Skip to main content

Table 1 Baseline routine and specific laboratory investigations of the studied groups

From: Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients

Lab investigations Total cases (No. = 280) Test of significance P value
Group I (No. = 140) Group II (No. = 80) Group III (No. = 60)
Mean ± SD Mean ± SD Mean ± SD
ALT (IU/ml) 58.6 ± 7.8 75.0 ± 20.6 122.0 ± 66.4 Kruskal-Wallis test = 17.6 < 0.001**
AST(IU/ml) 44.1 ± 13.3 65.0 ± 23.3 114.2 ± 67.6 Kruskal-Wallis test = 17.14 < 0.001**
ALP (IU/ml) 29.8 ± 14.8 75.1 ± 24.4 134.8 ± 68.8 Kruskal-Wallis test = 21.24 < 0.001**
GGT (IU/ml) 12.7 ± 7.5 30.1 ± 10.8 63.3 ± 12.1 Kruskal-Wallis test = 20.14 < 0.001**
Total bilirubin (mg/dl) 1.1 ± 0.27 1.2 ± 0.84 1.8 ± 1.2 Kruskal-Wallis test = 0.73 0.69
Albumin (g/dl) 3.8 ± 0.54 3.7 ± 0.39 3.4 ± 0.37 ANOVA test = 0.85 0.44
PT (s) 14.5 ± 2.1 14.5 ± 1.6 14.9 ± 2.2 ANOVA test = 0.08 0.92
PT concentration (%) 86.3 ± 19.5 86.8 ± 9.5 84.9 ± 13.9 ANOVA test = 0.05 0.95
INR 1.2 ± 0.17 1.2 ± 0.15 1.2 ± 0.18 ANOVA test = 0.09 0.91
Hb (gm/dl) 13.6 ± 1.7 13.6 ± 1.3 12.8 ± 2.8 ANOVA test = 0.41 0.67
PLT (X103/mm) 186.2 ± 48.3 189.9 ± 57.4 157.0 ± 62.6 Kruskal-Wallis test = 1.60 0.45
Glucose (mg/dl) 92.9 ± 30.5 90.1 ± 25.6 98.2 ± 36.9 Kruskal-Wallis test = 0.16 0.92
Creatinine(mg/dl) 0.81 ± 0.12 0.81 ± 0.09 0.83 ± 0.13 ANOVA test = 0.88 0.92
Urea (mg/dl) 35.0 ± 10.9 44.5 ± 9.1 39.5 ± 11.3 ANOVA test = 2.08 0.15